VolitionRx Limited (NYSE American: VNRX) has emphasized the mounting clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company also released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. According to the announcement, multiple studies have demonstrated that the Nu.Q H3.1 test can differentiate sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes such as organ failure and mortality.
Volition noted that most of the supporting research has been peer reviewed and published, with experts highlighting the consistency of findings across various countries and patient populations. The company believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies.
The press release, available at https://ibn.fm/2IH3m, details the growing body of evidence. Sepsis is a life-threatening condition that arises when the body's response to infection causes widespread inflammation, leading to tissue damage, organ failure, and potentially death. Early and accurate diagnosis is critical for effective treatment, and biomarkers like H3.1 nucleosomes could play a key role in improving patient outcomes.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, the company develops and commercializes simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The implications of this announcement are significant for the medical community and patients. If the Nu.Q NETs test becomes widely adopted, it could transform sepsis management by enabling earlier detection and more personalized treatment plans. This could potentially reduce mortality rates and healthcare costs associated with sepsis. The consistency of findings across multiple studies and populations strengthens the case for the test's clinical utility. As VolitionRx continues to gather evidence and engage with the medical community through educational initiatives like the video with Dr. Retter, the path toward broader clinical implementation becomes clearer. For more information about VolitionRx, visit the company's website at https://volition.com/.
